Compare STXS & ANIK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | STXS | ANIK |
|---|---|---|
| Founded | 1990 | 1983 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 183.7M | 198.9M |
| IPO Year | 2004 | 1996 |
| Metric | STXS | ANIK |
|---|---|---|
| Price | $1.62 | $14.78 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 1 |
| Target Price | $4.00 | ★ $17.00 |
| AVG Volume (30 Days) | ★ 382.4K | 57.2K |
| Earning Date | 05-12-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 16.67 | ★ 80.16 |
| EPS | ★ N/A | N/A |
| Revenue | $29,346,617.00 | ★ $112,819,000.00 |
| Revenue This Year | $28.22 | $5.98 |
| Revenue Next Year | $30.47 | $7.42 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.61 | $7.90 |
| 52 Week High | $3.59 | $16.24 |
| Indicator | STXS | ANIK |
|---|---|---|
| Relative Strength Index (RSI) | 34.40 | 50.14 |
| Support Level | N/A | $13.91 |
| Resistance Level | $1.99 | $15.08 |
| Average True Range (ATR) | 0.10 | 0.50 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 3.95 | 62.04 |
Stereotaxis Inc is engaged in robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. The company's mission is the discovery, development, and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. The company's revenue generation is derived from the streams of Systems, Disposables, Royalty, and Sublease, of which a majority of revenue is generated from the Disposables, service, and accessories stream.
Anika Therapeutics Inc operates in the OA Pain Management and regenerative solutions space, focusing on early intervention orthopedics. The company leverages proprietary hyaluronic acid (HA) technology to develop differentiated products and provides products and services. Its OA Pain Management products include Orthovisc, Monovisc, and Cingal. Monovisc and Orthovisc are single- and multi-injection HA viscosupplement products indicated for pain relief from OA conditions and are generally administered to patients in an office setting. In the United States, Monovisc and Orthovisc are marketed exclusively by Johnson & Johnson MedTech. It generates maximum revenue from the OEM Channel and derives the majority of its revenue from the United States, with a presence in Europe and other countries.